Montelukast Pensa (Montelukast Sodium)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotriene D4 and related mediators from binding. This inhibition reduces bronchial smooth‑muscle contraction, vascular leakage, mucus production, and inflammatory cell recruitment, thereby improving airway function and reducing allergic inflammation.

The specific dose of Montelukast is determined by the prescribing healthcare professional based on the patient’s age, condition, and response to therapy. Dosage forms and strengths are selected to match the clinician’s recommendation, and patients should follow the prescribed regimen exactly.

Safety data for Montelukast during pregnancy are limited, and the medication should only be used if the potential benefit justifies any possible risk to the fetus. While limited information exists for breastfeeding, the decision to continue treatment should be made after weighing the infant’s exposure against the mother’s therapeutic need.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Montelukast Pensa. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with aspirin‑exacerbated respiratory disease or those who prefer a once‑daily tablet. While effective for many, it may be less potent than inhaled steroids for severe persistent asthma, and clinicians often use it as add‑on therapy.

Montelukast Pensa should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and excessive heat. Keep the product out of reach of children and avoid exposing it to direct sunlight or humid environments.

Montelukast is taken orally, usually once daily in the evening, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare provider to maintain consistent drug levels.

Serious adverse events include allergic reactions such as rash, angioedema, or anaphylaxis; neuropsychiatric effects like depression, mood swings, or suicidal thoughts; and rare conditions such as eosinophilic granulomatosis with polyangiitis. Patients should seek immediate medical attention if they experience any of these symptoms.

Montelukast is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Caution is advised for patients with severe liver impairment, active psychiatric disorders, or those taking strong enzyme‑inducing medications that may diminish its effectiveness.